BioScrip (NASDAQ:BIOS) reported Q1 2018 earnings this Morning, coming in at ($0.12) per share, missing Wall Street’s estimates of ($0.11) per Share. Revenue for the quarter came in at $168.60 million beating analyst estimates of $164.72 million Recent Insider Trading for BioScrip (NASDAQ:BIOS)
- On 11/9/2017 Daniel E Greenleaf, CEO, bought 15,000 with an average share price of $2.03 per share and the total transaction amounting to $30,450.00.
- On 11/9/2017 Stephen Deitsch, CFO, bought 10,000 with an average share price of $2.03 per share and the total transaction amounting to $20,300.00.
- On 9/15/2017 Michael G Bronfein, Director, sold 27,000 with an average share price of $2.69 per share and the total transaction amounting to $72,630.00.
- On 9/7/2017 Coliseum Capital Management, L, Director, sold 2,846,941 with an average share price of $2.93 per share and the total transaction amounting to $8,341,537.13.
- On 8/17/2017 Coliseum Capital Management, L, Director, sold 886,478 with an average share price of $3.08 per share and the total transaction amounting to $2,730,352.24.
- On 11/11/2016 Jeffrey M Kreger, CFO, bought 10,000 with an average share price of $1.32 per share and the total transaction amounting to $13,200.00.
Dividend History for BioScrip (NASDAQ:BIOS)
Recent Trading for BioScrip (NASDAQ:BIOS) Shares of BioScrip closed the previous trading session at 2.67 up +0.04 1.52% with 2.740000009536743 shares trading hands.